Non-small cell lung cancer

News

Image of a pair of lungs on an orange-beige background

Pfizer's Seagen-derived ADC pipeline suffers a setback

One of the antibody-drug conjugates at the heart of Pfizer's $43bn acquisition of Seagen three years ago has failed a phase 3 lung cancer trial.

News

Boehringer advances duo for aggressive cancers into phase 3

Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.

News

ASCO26: Lilly's Retevmo aces early-stage lung cancer trial

Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.

News

ASCO26: Ivonescimab improves survival in NSCLC

Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.

News

Dizal breaks new ground for EGFR drugs in lung cancer

Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.

News

Immutep investors spooked by LAG-3 failure in lung cancer

Friday the 13th has turned into a horror story for Immutep, whose share price has collapsed after it abandoned a pivotal trial of its LAG-3 drug efti.

Pfizer's Seagen-derived ADC pipeline suffers a setback

Boehringer advances duo for aggressive cancers into phase 3

ASCO26: Lilly's Retevmo aces early-stage lung cancer trial

ASCO26: Ivonescimab improves survival in NSCLC

Dizal breaks new ground for EGFR drugs in lung cancer

Immutep investors spooked by LAG-3 failure in lung cancer

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

Non-small cell lung cancer

Editor's Picks